Ritholtz Wealth Management Has $704,000 Stake in Fresenius Medical Care AG (NYSE:FMS)

Ritholtz Wealth Management boosted its stake in Fresenius Medical Care AG (NYSE:FMS) by 2.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,901 shares of the company’s stock after buying an additional 895 shares during the quarter. Ritholtz Wealth Management’s holdings in Fresenius Medical Care were worth $704,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of FMS. VisionPoint Advisory Group LLC acquired a new stake in Fresenius Medical Care in the 4th quarter valued at $812,000. QRG Capital Management Inc. raised its position in Fresenius Medical Care by 44.9% in the 4th quarter. QRG Capital Management Inc. now owns 45,493 shares of the company’s stock valued at $948,000 after purchasing an additional 14,100 shares during the last quarter. Partnership Wealth Management LLC bought a new position in Fresenius Medical Care in the 4th quarter valued at $2,340,000. Moran Wealth Management LLC bought a new position in Fresenius Medical Care in the 4th quarter valued at $3,247,000. Finally, Guardian Capital Advisors LP raised its position in Fresenius Medical Care by 16.7% in the 4th quarter. Guardian Capital Advisors LP now owns 123,715 shares of the company’s stock valued at $2,556,000 after purchasing an additional 17,725 shares during the last quarter. Institutional investors and hedge funds own 8.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on FMS shares. StockNews.com started coverage on Fresenius Medical Care in a research report on Thursday, August 29th. They set a “strong-buy” rating for the company. Truist Financial reduced their target price on shares of Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday, July 31st. One analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $22.00.

Fresenius Medical Care Trading Down 1.0 %

NYSE FMS opened at $19.20 on Wednesday. The stock has a 50-day simple moving average of $19.29 and a 200 day simple moving average of $19.87. The company has a market capitalization of $11.27 billion, a PE ratio of 21.57, a P/E/G ratio of 1.03 and a beta of 0.90. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. Fresenius Medical Care AG has a 12 month low of $16.37 and a 12 month high of $23.29.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, meeting analysts’ consensus estimates of $0.38. The business had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.28 billion. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. Research analysts forecast that Fresenius Medical Care AG will post 1.51 EPS for the current year.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.